Annals of the Rheumatic Diseases collection on lupus nephritis (2019–2022): novel insights and advances in therapy-Reference-Cited by-同舟云学术

Annals of the Rheumatic Diseases collection on lupus nephritis (2019–2022): novel insights and advances in therapy

Published:2023-04-24 Issue:6 Volume:82 Page:729-733
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Ann Rheum Dis

Author:

Kostopoulou Myrto^ORCID,Fanouriakis Antonis^ORCID,Bertsias George,Boumpas Dimitrios T^ORCID

Abstract

No single organ has received as much attention in systemic lupus erythematosus (SLE) as the kidneys. During the period 2019–2022, theAnnals of the Rheumatic Diseasespublished several original papers, brief reports and letters that further elucidate the pathogenesis and advance the management of LN. A selection of representative original papers is highlighted in this review.

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Reference35 articles.

1. All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971–2013)

2. High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus

3. Interaction between the STAT4 rs11889341(T) risk allele and smoking confers increased risk of myocardial infarction and nephritis in patients with systemic lupus erythematosus

4. Interferon-α enhances the IL-12-induced STAT4 activation selectively in carriers of the STAT4 SLE risk allele rs7574865[T]

5. Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Demethylzeylasteral ameliorates podocyte damage in murine lupus by inhibiting inflammation and enhancing autophagy;Phytomedicine;2024-11

2. Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years;Annals of the Rheumatic Diseases;2024-05-23

3. Exosomes in Action: Unraveling Their Role in Autoimmune Diseases and Exploring Potential Therapeutic Applications;Immune Network;2024

4. Greetings from the editor 2024;Annals of the Rheumatic Diseases;2024-01

5. Greetings from the editor 2023/2;Annals of the Rheumatic Diseases;2023-05-11